EGFR and neoplasm: Everolimus, an mTOR inhibitor, showed no HR or RR,14,15 which could be related to incomplete target inhibition in the tumor tissue as observed by a recent phase 0 study.34 Lapatinib, a TKI targeting HER1 and HER2, was well-tolerated and produced HR in 4 patients (31%) and RR in 1 patient (6%).